Clinical Trial Detail

NCT ID NCT02220842
Title A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

Atezolizumab + Obinutuzumab

Age Groups: adult

No variant requirements are available.